greeksoup/ stock research
Stock research / United States / AZN / Filings

AstraZeneca PLC SEC filings

In the twelve months since 29 September 2025 AstraZeneca PLC filed 123 documents with the SEC of the kinds listed here: 117 reports on Form 6-K, most often 12 director/PDMR shareholding; 10 total voting rights; 4 admission of further securities to trading; 3 directorate change; 2 total voting rights and admission of shares; 3 delisting notice by the exchanges (25-NSE), 1 employee plan annual report (11-K), 1 annual report (foreign filer) (20-F), 1 employee share plan registration (S-8). The latest, filed 23 September 2026: 6-K, trixeo approved in eu for asthma.

FiledFormWhat it was aboutPeriod or event dateFiling
23 September 20266-KTrixeo approved in EU for asthma23 September 2026EDGAR
21 September 20266-KKlygefa recommended for EU approval by CHMP21 September 2026EDGAR
21 September 20266-KEnhertu recommended for approval in EU in early BC21 September 2026EDGAR
18 September 20266-KDirector/PDMR shareholding18 September 2026EDGAR
15 September 20266-KDirector/PDMR shareholding15 September 2026EDGAR
15 September 20266-KDirector/PDMR shareholding15 September 2026EDGAR
14 September 20266-KUpdate on serena-4 phase III trial14 September 2026EDGAR
8 September 20266-KImfinzi+imdelltra improved OS in small CELL LUNG8 September 2026EDGAR
8 September 20266-KEtcamah approved in the US for HR+ breast cancer8 September 2026EDGAR
1 September 20266-KAdmission of further securities to trading1 September 2026EDGAR
1 September 20266-KTotal voting rights1 September 2026EDGAR
1 September 20266-KAdmission to trading - EUR2.55 billion bond offering1 September 2026EDGAR
1 September 20266-KEnhertu approved in EU for 1L HER2-positive MBC1 September 2026EDGAR
1 September 20266-KDirectorate change1 September 2026EDGAR
1 September 20266-KAstrazeneca completes agreement for zegfrovy1 September 2026EDGAR
1 September 20266-KTagrisso + orpathys improved PFS in 1L egfrm LUNG1 September 2026EDGAR
27 August 20266-KTezspire crossing trial MET primary endpoints27 August 2026EDGAR
25 August 20266-KAstrazeneca prices a EUR2.55 billion bond offering25 August 2026EDGAR
19 August 20266-KDirector/PDMR shareholding19 August 2026EDGAR
17 August 20266-KEnhertu improved PFS in 1L HER2M LUNG cancer17 August 2026EDGAR
17 August 20266-KUpdate on evolve-LUNG02 phase III trial17 August 2026EDGAR
17 August 20266-KTagrisso+orpathys improved PFS & OS in egfrm LUNG17 August 2026EDGAR
3 August 20266-KAdmission of further securities to trading3 August 2026EDGAR
3 August 20266-KTotal voting rights3 August 2026EDGAR
31 July 20266-KDatroway approved in EU for TNBC31 July 2026EDGAR
27 July 20266-KUpdate on ultomiris phase III trial in HSCT-TMA27 July 2026EDGAR
27 July 20266-KSONE-VE improved survival in gastric cancers27 July 2026EDGAR
27 July 20266-Kno title given to EDGAR; the filing is linked30 June 2026EDGAR
23 July 20266-KEtcamah approved in the EU for ER+ breast cancer23 July 2026EDGAR
14 July 20266-KAstrazeneca licenses novel EGFR inhibitor14 July 2026EDGAR
9 July 20266-KUpdate on cardio-ttransform phase III trial9 July 2026EDGAR
1 July 20266-KAdmission of further securities to trading1 July 2026EDGAR
1 July 20266-KTotal voting rights1 July 2026EDGAR
29 June 202611-Kemployee plan annual report31 December 2025EDGAR
29 June 20266-KEnhertu approved in EU for HER2+ solid tumours29 June 2026EDGAR
29 June 20266-KDatroway recommended for approval in EU for TNBC29 June 2026EDGAR
15 June 20266-KTruqap approved in US for prostate cancer15 June 2026EDGAR
1 June 20266-KAdmission of further securities to trading1 June 2026EDGAR
1 June 20266-KTotal voting rights1 June 2026EDGAR
29 May 20266-KImfinzi approved in US for early bladder cancer29 May 2026EDGAR
28 May 202625-NSEdelisting notice by the exchangeEDGAR
27 May 20266-KUS FDA decision date on camizestrant extended27 May 2026EDGAR
26 May 20266-KDatroway approved in US for 1L triple-negative BC26 May 2026EDGAR
26 May 20266-KEnhertu recommended in EU for HER2+ solid tumours26 May 2026EDGAR
26 May 20266-KCamizestrant recommended for breast cancer in EU26 May 2026EDGAR
18 May 20266-KDirector/PDMR shareholding18 May 2026EDGAR
18 May 20266-KBaxfendy approved in the US for hypertension18 May 2026EDGAR
18 May 20266-KEnhertu approved in two HER2+ early BC settings18 May 2026EDGAR
14 May 20266-KImfinzi + EV improves EFS & OS in bladder cancer14 May 2026EDGAR
1 May 20266-KTotal voting rights and admission of shares1 May 2026EDGAR
1 May 20266-KFDA ODAC vote on camizestrant in breast cancer1 May 2026EDGAR
1 May 20266-KFDA ODAC recommends truqap in prostate cancer1 May 2026EDGAR
29 April 20266-K1ST quarter results29 April 2026EDGAR
28 April 20266-KBreztri approved in the US for asthma28 April 2026EDGAR
27 April 20266-KSaphnelo SELF-administration approved in the US27 April 2026EDGAR
23 April 20266-KDirectorate change23 April 2026EDGAR
21 April 20266-KI CAN phiii interim analysis MET primary endpoint21 April 2026EDGAR
20 April 20266-KThird tozorakimab positive phase III in COPD20 April 2026EDGAR
9 April 20266-KResult of AGM9 April 2026EDGAR
8 April 202625-NSEdelisting notice by the exchangeEDGAR
2 April 20266-KImfinzi+imjudo improves PFS in early liver cancer2 April 2026EDGAR
1 April 20266-KTotal voting rights and admission of shares1 April 2026EDGAR
31 March 20266-KEfzimfotase ALFA PH3 program SHOW positive results31 March 2026EDGAR
27 March 20266-KTozorakimab MET oberon/titania primary endpoints27 March 2026EDGAR
20 March 20266-KNotification of admission of shares20 March 2026EDGAR
16 March 20266-KImfinzi approved in EU for early gastric cancer16 March 2026EDGAR
10 March 20266-KNotice of AGM10 March 2026EDGAR
10 March 20266-Kno title given to EDGAR; the filing is linked10 March 2026EDGAR
6 March 20266-KDirector/PDMR shareholding6 March 2026EDGAR
6 March 20266-KDirector/PDMR shareholding6 March 2026EDGAR
6 March 20266-KDirector/PDMR shareholding6 March 2026EDGAR
2 March 20266-KTotal voting rights2 March 2026EDGAR
2 March 20266-Kno title given to EDGAR; the filing is linked2 March 2026EDGAR
26 February 20266-KAstrazeneca prices a $2BN bond offering26 February 2026EDGAR
25 February 20266-KFiling of form 20-f with SEC25 February 2026EDGAR
24 February 20266-KAnnual financial report24 February 2026EDGAR
24 February 20266-KDirectorate change24 February 2026EDGAR
24 February 202620-Fannual report (foreign filer)31 December 2025EDGAR
24 February 20266-Kno title given to EDGAR; the filing is linked24 February 2026EDGAR
20 February 20266-KFixed-duration calquence combo approved in US20 February 2026EDGAR
10 February 20266-KFinal results10 February 2026EDGAR
3 February 20266-KUpdate on saphnelo subcutaneous administration3 February 2026EDGAR
2 February 20266-KTotal voting rights2 February 2026EDGAR
2 February 20266-KImfinzi recommended in EU for early gastric cancer2 February 2026EDGAR
2 February 20266-KAstrazeneca begins trading on NYSE2 February 2026EDGAR
2 February 2026S-8employee share plan registrationEDGAR
30 January 20266-KAstrazeneca agrees obesity and T2D deal with CSPC30 January 2026EDGAR
29 January 20266-KAstrazeneca invests $15BN in china through 203029 January 2026EDGAR
20 January 20266-KAstrazeneca to complete direct listing on NYSE20 January 2026EDGAR
8 January 20266-KAZN new HEAD of investor relations joris silon8 January 2026EDGAR
2 January 20266-KTotal voting rights2 January 2026EDGAR
22 December 20256-KDirector/PDMR shareholding22 December 2025EDGAR
22 December 20256-KEnhertu granted BTD for post-neoadjuvant early BC22 December 2025EDGAR
22 December 20256-KUpdate on latify phase III trial of ceralasertib22 December 2025EDGAR
19 December 20256-KDirector/PDMR shareholding19 December 2025EDGAR
16 December 20256-KSubcutaneous saphnelo approved in EU16 December 2025EDGAR
16 December 20256-KEnhertu approved in US for 1L HER2+ metastatic BC16 December 2025EDGAR
4 December 20256-KHolding(s) in company4 December 2025EDGAR
1 December 20256-KBlock listing interim review1 December 2025EDGAR
1 December 20256-KTotal voting rights1 December 2025EDGAR
26 November 20256-KImfinzi approved in US for early gastric cancer26 November 2025EDGAR
24 November 20256-KAstrazeneca manufacturing investment in maryland24 November 2025EDGAR
20 November 20256-KKoselugo (selumetinib) approved in the US20 November 2025EDGAR
17 November 20256-KHolding(s) in company17 November 2025EDGAR
14 November 20256-KDirector/PDMR shareholding14 November 2025EDGAR
14 November 202525-NSEdelisting notice by the exchangeEDGAR
10 November 20256-KDirector/PDMR shareholding10 November 2025EDGAR
6 November 20256-K9M and q3 2025 results6 November 2025EDGAR
3 November 20256-KResult of general meeting3 November 2025EDGAR
3 November 20256-KTotal voting rights3 November 2025EDGAR
3 November 20256-Kno title given to EDGAR; the filing is linked3 November 2025EDGAR
28 October 20256-KDirector declaration28 October 2025EDGAR
28 October 20256-KKoselugo (selumetinib) approved in the EU28 October 2025EDGAR
22 October 20256-KTezspire approved in EU for crswnp22 October 2025EDGAR
20 October 20256-KUS FDA approves tezspire in crswnp20 October 2025EDGAR
20 October 20256-KPositive CHMP opinion for subcutaneous saphnelo20 October 2025EDGAR
14 October 20256-KAgreement with US GOVT to lower medicine prices14 October 2025EDGAR
7 October 20256-KBaxdrostat MET primary endpoint in BAX24 PH3 trial7 October 2025EDGAR
6 October 20256-KDatroway improved OS and PFS in tropion-breast026 October 2025EDGAR
1 October 20256-KTotal voting rights1 October 2025EDGAR
29 September 20256-KEnhertu improved IDFS in early BC in DB-0529 September 2025EDGAR
29 September 20256-KAZN harmonises listing structure29 September 2025EDGAR
29 September 20256-Kno title given to EDGAR; the filing is linked29 September 2025EDGAR

A foreign company listed in the US files a Form 6-K for what it publishes at home: results, share buybacks, directors' dealings, bond issues and notices. The 6-K carries no item numbers, so each is listed under the title the company gave EDGAR, where it gave one; the rest are linked to the filing itself. The annual report is the 20-F (or the 40-F for a Canadian filer). Form 144, 13F and Schedule 13D and 13G have their own pages; a foreign filer files no Form 4.

Source

The company's filing index on EDGAR, read from the SEC's submissions feed.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install